ESPE Abstracts

Background: Prader-Willi Syndrome (PWS), is a rare complex, genetic neurodevelopmental disorder characterised by hypotonia, poor feeding, neonatal failure to thrive. Untreated, patients progress to hyperphagia and life-limiting extreme obesity. Growth hormone therapy (GHt) is currently the only licenced therapy in PWS. The consensus statement by Deal et al, suggested GH treatment at around 2-years before the onset of obesity. While there are no data to support...